Plasma B-type natriuretic peptide for early diagnosis of allograft rejection after renal transplantation

Medical Hypotheses
T SunL Wang

Abstract

B-type natriuretic peptides are predominantly synthesized in the ventricular myocytes. This is the response to volume overload or increased stress to the ventricular wall. Plasma B-type natriuretic peptide levels are elevated in patients with chronic renal failure due to reduced glomerular filtration and/or increased myocardial biosynthesis. Allograft renal transplantation significantly reduces plasma B-type natriuretic peptide. Our previous clinical observations have demonstrated that acute allograft renal rejection is associated with a sudden increase in plasma B-type natriuretic peptides. We hypothesized that plasma B-type natriuretic peptide may be used as a sensitive and specific biomarker for clinical diagnosis of acute allograft renal rejection.

References

Jul 31, 1998·The New England Journal of Medicine·E R LevinW K Samson
Jan 12, 2000·Current Opinion in Nephrology and Hypertension·A Chandraker
Mar 4, 2000·The New England Journal of Medicine·S HariharanD Stablein
Jul 31, 2001·Cardiovascular Research·B C Kone
Oct 6, 2001·The New England Journal of Medicine·J A de LemosE Braunwald
Jul 19, 2002·The New England Journal of Medicine·Alan S MaiselUNKNOWN Breathing Not Properly Multinational Study Investigators
Jul 5, 2003·American Journal of Physiology. Renal Physiology·David L Vesely
Nov 22, 2005·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Walter H Hörl
Apr 21, 2006·Archives of Medical Research·Tongwen SunYanzhou Zhang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.